Lancaster General Health is a regional health system in Lancaster, Pennsylvania. It is part of the University of Pennsylvania Health System. Its flagship hospital is Lancaster General Hospital.

There are 631 beds in Lancaster General Hospital.

During the past decade, Lancaster General Hospital conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 64 clinical trials were completed, i.e. on average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 28 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lancaster General Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 35 trials, followed by "Abbott Medical Devices" with 9 trials sponsored, "Lancaster General Hospital" with 8 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 8 trials sponsored and "SWOG Cancer Research Network" with 8 trials sponsored. Other sponsors include 83 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lancaster General Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 36 trials as a collaborator, "NRG Oncology" with 15 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator, "NCIC Clinical Trials Group" with 9 trials as a collaborator and "SWOG Cancer Research Network" with 7 trials as a collaborator. Other collaborators include 64 different institutions and companies that were collaborators in the rest 49 trials.

According to Clinical.Site data, the most researched conditions in "Lancaster General Hospital" are "Heart Failure" (22 trials), "Breast Cancer" (14 trials), "Lung Cancer" (8 trials), "Breast Adenocarcinoma" (5 trials) and "Gliosarcoma" (4 trials). Many other conditions were trialed in "Lancaster General Hospital" in a lesser frequency.

Most popular intervention types in "Lancaster General Hospital" are "Drug" (83 trials), "Other" (52 trials), "Device" (36 trials), "Biological" (31 trials) and "Radiation" (20 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (22 trials), "Placebo" (19 trials), "Quality-of-Life Assessment" (19 trials), "Bevacizumab" (12 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "Lancaster General Hospital" are 132 trials for "All" genders, 23 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Lancaster General Hospital". undefined are not yet recruiting, 18 are recruiting, 47 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 68 completed trials in Lancaster General Hospital, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Lancaster General Hospital, 1 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 78 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 32 trials that are defined as “Not Applicable".